Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors

Brief description of study

This study is about a new medicine called ICVB-1042 (kills tumor cells) for people with advanced solid tumors. It has two parts: one where we figure out the right dose that has few side effects and is safe for patients to consume, and another where we see if it works in treating the advanced solid tumors. We'll test it on patients who've had cancer get worse even after trying other treatments. Patients will participate in the study for a few months. ICVB-1042 will be given through a vein on three different days out of a 7-day treatment period. The main goal is to make sure the medicine has few side effects and to find the best dose to use in future studies that will treat advanced solid tumors. We'll also check how the medicine moves in the body and if the body makes any "anti-drug" reactions.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.